上海毕得医药科技股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为进一步完善上海毕得医药科技股份有限公司（以下简称"公司"） 董事、高级管理人员的薪酬管理，建立科学有效的激励与约束机制，有效调动 公司董事、高级管理人员的工作积极性，提高公司的经营管理效益，根据《中 华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关法律、法规及《上海毕得医药科技股份有限公司章程》（以下简称"公司 章程"），特制定本薪酬管理制度。 第二条 本制度适用于下列人员： （一） 董事（包括独立董事）； （二） 高级管理人员，包括总经理、副总经理、财务总监、董事会秘书以 及公司章程规定的其他高级管理人员。 第三条 公司薪酬制度遵循以下原则： （一） 公平原则，体现收入水平符合公司规模与业绩的原则，同时与外部 薪酬水平相符； （二） 责、权、利统一原则，体现薪酬与岗位价值高低、履行责任义务大 小相符； （三） 长远发展原则，体现薪酬与公司持续健康发展的目标相符； （四） 激励约束并重原则，体现薪酬发放与考核、奖惩、 ...

第一条 为规范上海毕得医药科技股份有限公司（以下简称"公司"）领导 人员的产生，优化董事会组成，完善公司治理结构，根据《中华人民共和国公司 法》、《上市公司治理准则》、《上海毕得医药科技股份有限公司章程》（以下简称 "公司章程"）及其他有关规定，依据公司股东会的相关决议，公司特设立董事 会提名委员会，并制定本工作细则。 第二条 董事会提名委员会（以下简称"提名委员会"）是董事会设立的专 门工作机构，主要负责对公司董事、高级管理人员的人选、选择标准和程序等事 项进行选择并提出建议。 本工作细则所称高级管理人员，是指公司的总经理、副总经理、董事会秘书、 财务总监。 上海毕得医药科技股份有限公司 董事会提名委员会工作细则 第一章 总则 第二章 人员组成 第三条 提名委员会成员由三名董事组成，其中独立董事占多数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或全体董事三分 之一以上（包括三分之一）提名，并由董事会选举产生。 选举委员的提案获得通过后，新任委员在董事会会议结束后立即就任。 第五条 提名委员会设主任委员（召集人）一名，由独立董事委员担任，负 责主持委员会工作，主任委员在委员内选举。 第六条 提名委 ...

上海毕得医药科技股份有限公司 董事、高级管理人员离职管理制度 第二章 离职情形与生效条件 第三条 董事可以在任期届满以前辞任。董事辞任应向公司提交书面辞任报 告。董事辞任的，自公司收到辞任报告之日辞任生效，公司将在两个交易日内 披露有关情况。出现下列规定情形的，在改选出的董事就任前，原董事仍应当 依照法律、行政法规和公司章程规定，履行董事职务： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员 低于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员低于法定最低人数，或者 欠缺担任召集人的会计专业人士； （三）独立董事辞任导致公司董事会或者专门委员会中独立董事所占比例 不符合法律法规或者公司章程规定，或者独立董事中欠缺会计专业人士。 第一章 总则 第一条 为规范上海毕得医药科技股份有限公司（以下简称"公司"）董事、 高级管理人员离职管理，保障公司治理稳定性及股东合法权益，根据《中华人 民共和国公司法》（以下简称《公司法》）《上市公司章程指引》《上海证券交易 所科创板股票上市规则》等法律法规、规范性文件及《上海毕得医药科技股份 有限公司章程》（以下简称"公司章程"）的有关规定，结合公司实际 ...

证券代码：688073 证券简称：毕得医药 公告编号：2026-005 上海毕得医药科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 2 月 9 日 9 点 30 分 召开地点：上海市杨浦区翔殷路 999 号 3 幢 6 层会议室 （五） 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 9 日 至2026 年 2 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2026年2月9日 本次股东会采用的网络投票系统：上海证 ...

南财智讯1月23日电，毕得医药公告，公司控股股东、实际控制人兼董事长、总经理戴岚女士通过集中 竞价交易方式累计减持公司股份148,835股，占公司总股本的0.16%，本次减持计划已实施完毕。 ...

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

Group 1 - Bid Medicine's stock price fell by 5.04% on January 20, closing at 66.00 yuan per share, with a trading volume of 52.74 million yuan and a turnover rate of 1.81%, resulting in a total market capitalization of 5.998 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.12% during this period [1] - Bid Medicine focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] Group 2 - Among the top ten circulating shareholders of Bid Medicine, a fund under E Fund, specifically E Fund Value Growth Mixed Fund (110010), entered the top ten with 900,000 shares, accounting for 2.08% of circulating shares [2] - The estimated floating loss for E Fund Value Growth Mixed Fund today is approximately 3.15 million yuan, with a total floating loss of 4.077 million yuan during the three-day decline [2] - E Fund Value Growth Mixed Fund has a total asset size of 3.288 billion yuan, with a year-to-date return of 3.74% and a one-year return of 38.06% [2]

Market Overview - On January 13, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index closing at 4163.84 points, down 0.03% [2] - The Shenzhen Component Index fell by 0.31%, and the ChiNext Index decreased by 0.83% [2][3] - A total of 2427 stocks rose while 2862 stocks fell, indicating a mixed market sentiment [3] Sector Performance - The healthcare services, lithium mining, precious metals, and insurance sectors showed strong performance, while sectors such as commercial aerospace, communication equipment, and shipbuilding faced declines [3][4] - Lithium mining stocks experienced a significant surge, with companies like Tibet Summit reaching a 10% limit up, and others like Salt Lake Co. and Ganfeng Lithium rising over 7% [6][7] Lithium Mining Sector - The lithium mining sector saw a notable rally, with the main contract for lithium carbonate futures on the Shanghai Futures Exchange surpassing 170,000 yuan per ton, marking a rise of over 9% [6] - Key stocks in this sector include: - Tibet Summit: 19.49 yuan, up 9.99%, market cap of 17.8 billion yuan - Ganfeng Lithium: 72.83 yuan, up 7.15%, market cap of 144.5 billion yuan - Salt Lake Co.: 34.24 yuan, up 7.13%, market cap of 181.2 billion yuan [7] Insurance Sector - The financial sector was active, with the insurance sector showing strength. China Life Insurance rose over 3%, reaching 50.94 yuan per share, with a market cap of 1.2794 trillion yuan [10] - China Ping An increased by over 2%, priced at 68.92 yuan per share, with a market cap of 1.2034 trillion yuan [12] - Analysts predict that by 2026, new premium income for listed insurance companies will achieve double-digit growth, driven primarily by the bancassurance channel [15] AI Healthcare Sector - AI healthcare stocks were notably active, with several companies hitting the daily limit up. Notable performers included: - Nossg: 76.48 yuan, up 20.01%, market cap of 7.4 billion yuan - Pruis: 72.24 yuan, up 20.00%, market cap of 5.7 billion yuan - Hongbo Medicine: 56.64 yuan, up 20.00%, market cap of 7.9 billion yuan [18] - Nvidia announced a joint investment of $1 billion with Eli Lilly to establish an AI drug laboratory, which is expected to accelerate medical discoveries [17] Precious Metals Sector - The precious metals sector saw a significant rise, with spot gold prices reaching a record high of $4630.28 per ounce [20] - Key stocks in this sector include: - Hunan Silver: 9.21 yuan, up 9.90%, market cap of 26 billion yuan - Xiaocheng Technology: 38.54 yuan, up 8.72%, market cap of 10.6 billion yuan [21]

Group 1 - Bid Pharma's stock increased by 5.07% to 68.44 CNY per share, with a trading volume of 68.3753 million CNY and a turnover rate of 2.38%, resulting in a total market capitalization of 6.22 billion CNY [1] - The company, established on April 27, 2007, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Morgan Stanley Fund has a significant holding in Bid Pharma, with the "Morgan Stanley Youyue Anhe Mixed A" fund reducing its holdings by 15,300 shares to 53,000 shares, representing 6.6% of the fund's net value, making it the third-largest holding [2] - The fund has a total scale of 29.6292 million CNY and has achieved a year-to-date return of 8.64%, ranking 427 out of 8,827 in its category, and a one-year return of 26.74%, ranking 4,492 out of 8,084 [2]

Group 1 - Bid Pharma announced that as of the disclosure date, shareholder Zhoushan Xinxie Enterprise Management Partnership holds approximately 4.72 million unrestricted shares, accounting for 5.19% of the total shares [1] - Shareholder Zhoushan Landan Enterprise Management Partnership holds about 3.58 million shares, representing 3.94% of the total shares, with approximately 6.95 thousand shares being restricted and about 3.51 million shares being unrestricted [1] - Shareholder Wu Bo holds approximately 785.8 thousand unrestricted shares, which is 0.86% of the total shares [1] Group 2 - Xinxie Management, Landan Management, and Wu Bo are acting in concert, collectively holding 10% of Bid Pharma's shares [1] - Due to liquidity needs, these shareholders plan to reduce their holdings within three months after the disclosure of the reduction plan, starting 15 trading days from the announcement [1] - Xinxie Management plans to reduce up to approximately 1.0361 million shares through block trading and up to approximately 363.5 thousand shares through centralized bidding, while Landan Management and Wu Bo have similar reduction plans [1]